(1) Background: After thyroid malignancy is ruled out, treatment options for multinodular goiter patients include surgery, levothyroxine suppressive therapy, and 131-I therapy. Surgery effectively reduces goiter size but carries risks of surgical and anesthetic complications. 131-I therapy is the only nonsurgical alternative, but its effectiveness diminishes with goiter size and depends on iodine sufficiency. This study aimed to assess the efficacy and safety of 0.1 mg rhTSH as an adjuvant to a fixed dose of 131-I therapy in patients with a recurrence of large multinodular goiter, several years after the initial thyroidectomy. (2) Methods: 14 patients (13 females and 1 male), aged 59.14 ± 15.44 (range, 35-78 years) received 11mciu of 131-I, 24 h after the administration of 0.1 mg rhTSH. The primary endpoint was the change in thyroid volume (by ultrasound measurements) as well as in the diameter of the predominant nodule during a follow-up period of 10 years. Secondary endpoints were the alterations in thyroid function and potential adverse effects. (3) Results: A significant decrease in the volume of initial thyroid remnants (32.16 ± 16.66 mL) was observed from the first reevaluation (at 4 months, 23.12 ± 11.59 mL) as well as at the end of the follow-up period (10 years, 12.62 ± 8.76 mL), < 0.01. A significant reduction in the dominant nodule was also observed (from 31.71 ± 10.46 mm in the beginning to 26.67 ± 11.05 mm). (4) Conclusions: Further investigation is needed since this approach could be attractive in terms of minimizing the potential risks of reoperation in these patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11083233 | PMC |
http://dx.doi.org/10.3390/diagnostics14090946 | DOI Listing |
Mymensingh Med J
January 2025
Dr Md Mominur Islam, Junior Consultant (ENT), Department of ENT & Head-Neck Surgery, Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh; E-mail:
Historically multi-nodular goiters have been thought of as a benign disease with a low risk of associated malignancy. Recent studies suggested that the incidence of malignancy in patients with MNG is not uncommon. With the aim of determining frequency of malignancy in multi-nodular goiter this cross sectional observational study was done at Mymensingh Medical College Hospital, Mymensingh, Bangladesh from June 2021 to March 2022.
View Article and Find Full Text PDFMalays J Pathol
December 2024
Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Pathology, Kuala Lumpur, Malaysia.
No abstract available.
View Article and Find Full Text PDFOncol Lett
March 2025
Department of Pathology, Beilun District People's Hospital of Ningbo City, Ningbo, Zhejiang 315000, P.R. China.
Renal cell carcinoma (RCC) is the most common malignancy that metastasizes to the thyroid; however, metastasis of RCC to a primary tumor of the thyroid is rare. The present study reports the case of RCC that had metastasized to the primary thyroid tumor; namely, a hyalinizing trabecular tumor (HTT). Notably, the RCC was resected 2 years prior.
View Article and Find Full Text PDFDiagn Cytopathol
December 2024
Department of Pathology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Introduction: Thyroid lesions are one of the most common diseases observed in clinical practice in the North India. These diseases have distinct cytological morphology and thus FNAC is done frequently. Here we report a case of adenomatoid goitre mimicking adenoid cystic carcinoma (ACC) of salivary gland on cytology.
View Article and Find Full Text PDFPan Afr Med J
December 2024
Endocrinology and Nutrition Department, Hospital General Universitario Santa Lucía, Murcia, Spain.
The thyroid is a rare site for finding tumor metastases. Renal, colorectal, pulmonary, and mammary origin are the most frequent primary neoplasms. Clinical suspicion, early diagnosis, and active surveillance are important during follow-up.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!